Cover Image

Midazolam pharmacokinetics in obese and non-obese children and adolescents

Midazolam is a first-line drug for the treatment of status epilepticus, both by buccal and intravenous administration. In children and adolescents with obesity, midazolam pharmacokinetics may be altered, and the current dosing guidelines may therefore be insufficient.

Saved in:
Bibliographic Details
Main Authors: Gade, Christina (Author) , Sverrisdóttir, Eva (Author) , Dalhoff, Kim (Author) , Sonne, Jesper (Author) , Johansen, Mia Østergaard (Author) , Christensen, Hanne Rolighed (Author) , Burhenne, Jürgen (Author) , Mikus, Gerd (Author) , Holm, Jens Christian (Author) , Lund, Trine Meldgaard (Author) , Holst, Helle (Author)
Format: Article (Journal)
Language:English
Published: 2020
In: Clinical pharmacokinetics
Year: 2019, Volume: 59, Issue: 5, Pages: 643-654
ISSN:1179-1926
DOI:10.1007/s40262-019-00838-1
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s40262-019-00838-1
Get full text
Author Notes:Christina Gade, Eva Sverrisdóttir, Kim Dalhoff, Jesper Sonne, Mia Østergaard Johansen, Hanne Rolighed Christensen, Jürgen Burhenne, Gerd Mikus, Jens Christian Holm, Trine Meldgaard Lund, Helle Holst
Description
Summary:Midazolam is a first-line drug for the treatment of status epilepticus, both by buccal and intravenous administration. In children and adolescents with obesity, midazolam pharmacokinetics may be altered, and the current dosing guidelines may therefore be insufficient.
Item Description:Published online: 19 November 2019
Gesehen am 08.06.2020
Physical Description:Online Resource
ISSN:1179-1926
DOI:10.1007/s40262-019-00838-1

Similar Items